Analyzing Bullfrog AI (NASDAQ:BFRG) and Enovis (NYSE:ENOV)

Enovis (NYSE:ENOV) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, risk, analyst recommendations, earnings, dividends and institutional ownership.

Analyst Recommendations

This is a summary of current recommendations for Enovis and Bullfrog AI, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1	0	6	0	2.71
Bullfrog AI	1	0	0	0	1.00

Enovis currently has a consensus price target of $51.17, suggesting a potential upside of 89.17%. Given Enovis’ stronger consensus rating and higher probable upside, research analysts clearly believe Enovis is more favorable than Bullfrog AI.

Volatility & Risk

Enovis has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Comparatively, Bullfrog AI has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500.

Profitability

This table compares Enovis and Bullfrog AI’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Enovis	-61.22%	7.79%	4.00%
Bullfrog AI	N/A	-218.25%	-177.11%

Institutional & Insider Ownership

98.5% of Enovis shares are held by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are held by institutional investors. 2.7% of Enovis shares are held by insiders. Comparatively, 25.2% of Bullfrog AI shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Enovis and Bullfrog AI”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.11 billion	0.73	-$825.49 million	($23.66)	-1.14
Bullfrog AI	$116,670.00	110.51	-$6.99 million	($0.69)	-1.64

Bullfrog AI has lower revenue, but higher earnings than Enovis. Bullfrog AI is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Summary

Enovis beats Bullfrog AI on 9 of the 14 factors compared between the two stocks.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.

About Bullfrog AI

Bullfrog AI Holdings, Inc., through its subsidiaries, operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform for the analysis of preclinical and/or clinical data. It also has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for the use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. The company was founded in 2017 and is based in Gaithersburg, Maryland.